SCHEMBL6777924

SCHEMBL6777924

COC(=O)c1cccc(NC(N)=NC#N)c1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.62
RAB9A P51151 6/20 0.56
SMN1; SMN2 Q16637 2/20 0.54
TP53 P04637 1/20 0.54
NPC1 O15118 4/20 0.53
MAPT P10636 4/20 0.51
MEN1 O00255 4/20 0.50
KMT2A Q03164 4/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
HTT P42858 1/20 0.49
POLB P06746 1/20 0.49
HPGD P15428 2/20 0.48
GPR17 Q13304 1/20 0.48
PPM1B O75688 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6777923 1.00 ALDH1A1 (0.62) ALDH1A1RAB9ASMN1; SMN2TP53NPC1
SCHEMBL23455503 1.00 ALDH1A1 (0.62) ALDH1A1RAB9ASMN1; SMN2TP53NPC1
SCHEMBL23489290 0.86 ALDH1A1 (0.62) ALDH1A1RAB9ASMN1; SMN2TP53NPC1
Water SCHEMBL8886628 0.85 KMT2A (0.50) ALDH1A1RAB9ASMN1; SMN2NPC1MEN1
SCHEMBL2347128 0.85 KMT2A (0.50) ALDH1A1RAB9ASMN1; SMN2NPC1MEN1
SCHEMBL2347131 0.85 KMT2A (0.50) ALDH1A1RAB9ASMN1; SMN2NPC1MEN1
Water SCHEMBL8886634 0.85 KMT2A (0.50) ALDH1A1RAB9ASMN1; SMN2NPC1MEN1
SCHEMBL23455453 0.85 KMT2A (0.50) ALDH1A1RAB9ASMN1; SMN2NPC1MEN1
SCHEMBL7350716 0.83 ALDH1A1 (0.54) ALDH1A1RAB9ASMN1; SMN2TP53NPC1
SCHEMBL6772415 0.83 RAB9A (0.59) ALDH1A1RAB9ASMN1; SMN2TP53NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0891325-B1 PARA-SUBSTITUTED PHENYLPROPANOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2002-02-06 EP disclosed
EP-1157985-A1 Para- substituted phenylene derivatives and their use as integrin antagonists G.D. SEARLE & CO. (US) 2001-11-28 EP disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6251944-B1 (VITRONECTIN RECEPTOR) INTEGRIN ANTAGONIST, USEFUL FOR TREATING ANGIOGENESIS, TUMOR GROWTH, TUMOR METASTASIS, OSTEOPOROSIS AND HUMORAL HYPERCALCEMIA OF MALIGNANCY G. D. SEARLE & COMPANY 2001-06-26 US disclosed
EP-0889875-B1 CYCLOPROPYL ALKANOIC ACID DERIVATIVES SEARLE & CO (US) 2001-06-20 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed
EP-0850221-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1998-07-01 EP disclosed
WO-1997008145-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1997-03-06 WO disclosed
US-5602277-A Substituted benzene derivatives useful as neuraminidase inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 1997-02-11 US disclosed
WO-1996030329-A1 SUBSTITUTED BENZENE DERIVATIVES USEFUL AS NEURAMINIDASE INHIBITORS BIOCRYST PHARMACEUTICALS, INCORPORATED (US) 1996-10-03 WO disclosed